ArticleNature communications2026
Engineering plasmids with synthetic origins of replication.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Rational engineering of combinatorial bacterial therapies for cancer.Genome biology · 2026Review
- How many plasmids can bacteria carry? A synthetic biology perspective.Open biology · 2025Review
- Transposon-plasmid nesting enables fast response to fluctuating environments.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Plasmids remain by far the most common medium for delivering engineered DNA to microorganisms. However, the reliance on natural plasmid replication mechanisms limits their tunability, compatibility, and modularity. Here we refactored the natural pMB1 origin and created plasmids with customizable copy numbers by tuning refactored components. We then created compatible origins that use synthetic RNA regulators to implement independent copy control. We further demonstrated that the synthetic origin of replication (SynORI) can be engineered modularly to respond to various signals, allowing for multiplexed copy-based reporting of environmental signals. Lastly, a library of 6 compatible SynORI plasmids was created and co-maintained in E. coli for a week. This work establishes the feasibility of creating plasmids with SynORI that can serve as a biotechnology for synthetic biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.